Proefschrift

Guerriero, M., Carbone, A., Colasurdo, F., Pellegrini, V., and Pollio, A. (2019). Sudden onset acute liver failure in a patient with clinically occult small cell lung carcinoma: autopsy report and review of the medical literature. Autopsy & Case Reports , 9(2):e2019089. 10 Gupta, S., Gallaher, J., Lynch, C., Cook, L., Araujo, A., Scott, J., Dhillon, J., Pow-Sang, J., and Basanta, D. (2015). Optimizing personalized treatment sequences in metastatic castration resistant prostate cancer using tumor-biomarker based computational modeling. Journal of Clinical Oncology , 33(15 suppl):e16014–e16014. 27 Hadjiandreou, M. and Mitsis, G. (2014). Mathematical modeling of tumor growth, drug- resistance, toxicity, and optimal therapy design. IEEE Transactions on Biomedical Engineering , 61(2):415–425. 14, 64 Hansen, E., Karslake, J., Woods, R., Read, A., and Wood, K. (2020). Antibiotics can be used to contain drug-resistant bacteria by maintaining sufficiently large sensitive populations. PLoS Biology , 18(5):e3000713. 11, 81, 97 Hansen, E. and Read, A. (2020). Cancer therapy: Attempt cure or manage drug resistance? Evolutionary Applications , 13(7):1660–1672. 97, 99 Hardin, G. (1960). The competitive exclusion principle. Science , 131:1292–1297. 76 Haridy, Y., Witzmann, F., Asbach, P., Schoch, R., Fro¨bisch, N., and Rothschild, B. (2019). Triassic Cancer—Osteosarcoma in a 240-Million-Year-Old Stem-Turtle. JAMA Oncology , 5(3):425–426. 3 Heller, G., McCormack, R., Kheoh, T., Molina, A., Smith, M., Dreicer, R., Saad, F., de Wit, R., Aftab, D., Hirmand, M., et al. (2018). Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: a comparison with prostate-specific antigen across five randomized phase III clinical trials. Journal of Clinical Oncology , 36(6):572–580. 98 Henry, K., Ulaner, G., and Lewis, J. (2017). Human epidermal growth factor receptor 2- targeted PET/single-photon emission computed tomography imaging of breast cancer: noninvasive measurement of a biomarker integral to tumor treatment and prognosis. PET Clinics , 12(3):269–288. 113 Higano, C., Beer, T., Taplin, M., Efstathiou, E., Hirmand, M., Forer, D., and Scher, H. (2015). Long-term safety and antitumor activity in the phase 1–2 study of enzalutamide in pre-and post-docetaxel castration-resistant prostate cancer. European Urology , 68(5):795– 801. 114 Hirata, Y., Akakura, K., Higano, C., Bruchovsky, N., and Aihara, K. (2012). Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression. Journal of Molecular Cel l Biology , 4(3):127–132. 11 174